Single-arm clinical trials are useful to evaluate antiretroviral regimens in certain populations of HIV-infected treatment-naive patients for whom a randomized controlled trial is not feasible or desirable. They can also be useful to establish initial estimates of efficacy and safety/tolerability of novel regimens to inform the design of large phase III trials. In this article, we discuss key design considerations for such single-arm studies.
Get full access to this article
View all access options for this article.
References
1.
Food, Drug Administration Guidance for Industry. Antiretroviral Drugs Using Plasma HIV RNA Measurements—Clinical Considerations for Accelerated and Traditional Approval. Appendix B. Division of Antiviral Drug Products: Office of Drug Evaluation IV in the Centre for Drug Evaluation and Research (CDER): Rockville, MD, 2002.
2.
Food and Drug Administration Guidance for Industry Non-Inferiority Clinical Trials: Draft March 2010. www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM202140.pdf. 2011 February 8.
3.
European Medicines Agency Committee for Medicinal Products for Human Use: EMA/CHMP Guideline on the Clinical Development of Medicinal Products for the Treatment of HIV Infection. September2009. www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003460.pdf. 2011 February 8.
4.
TaiwoB, ZhengL, GallienSet al.Efficacy of nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262)AIDS, 2011; 25:2113–2122.
5.
WeinstockH, RespessR, HeneineWet al.Prevalence of mutations associated with reduced antiretroviral drug susceptibility among human immunodeficiency virus type 1 seroconverters in the United States, 1993–1998. J Infect Dis, 2000; 182:330–333.
6.
JohnsonVA, Brun-VezinetF, ClotetBet al.Update of the drug resistance mutations in HIV-1: December 2008. Top HIV Med, 2008; 16:138–145.
7.
KalbfleischJD, PrenticeRL. The Statistical Analysis of Failure Time Data. John Wiley: Hoboken, NJ, 1980.
8.
GulickRM, RibaudoHJ, ShikumaCMet al.Three- vs. four-drug antiretroviral regimen for the initial treatment of HIV-1 infection: A randomized controlled trial. JAMA, 2006; 296:769–781.
9.
RiddlerSA, HaubrichR, DiRienzoAGet al.Class-sparing regimens for the initial treatment of HIV-1 infection. N Engl J Med, 2008; 358:2095–2106.
10.
MarkowitzM, NguyenBY, GotuzzoEet al.Rapid and durable antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: Results of a 48-week controlled study. J Acquir Immune Defic Syndr, 2007; 46:125–133.
11.
JennisonC, TurnbullBW. Group Sequential Tests with Applications to Clinical Trials. Chapman & Hall/CRC: Boca Raton, FL, 2000.
MolinaJM, CohenC, KatlamaCet al.The safety and efficacy of darunavir with low-dose ritonavir in treatment-experienced patients: 24 week results of POWER 3. J Acquir Immune Defic Syndr, 2007; 46:24–31.
14.
Food and Drug Industry Guidance for Industry: Chronic Hepatitis C Virus Infection: Developing Direct-Acting Antiviral Agents for Treatment (DRAFT GUIDANCE)September2010. www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM225333.pdf. 2011 November 8.
15.
SimonR. Optimal two-stage designs for phase II clinical trials. Control Clin Trials, 1989; 10:1–10.
16.
EnsignLG, GehanEA, KamenDS, ThallPF. An optimal three-stage design for phase II clinical trials. Stat Med, 1994; 13:1727–1736.
17.
JohnsonVE, CookJD. Bayesian design of single-arm phase II clinical trials with continuous monitoring. Clin Trials, 2009; 6:217–226.
